ArticleFrontiers in oncology2026
18F-FDG PET/CT metabolic network connectivity in clinical staging of diffuse large B-cell lymphoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common and highly heterogeneous subtype of non-Hodgkin lymphoma, and accurate staging is essential for treatment planning and prognosis. This study explored the value of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) metabolic network connectivity for the clinical staging of DLBCL. Methods: Forty-two previously untreated patients (23 males, 19 females; aged 30-82 years) diagnosed as Results: The degree Pearson correlation coefficient (DPCC) of the metabolic network differed significantly among stages II-IV (n=39, p<0.001) and between stage II (n=5) and stages III+IV (n=34) (p<0.001), whereas conventional metabolic, diffusion, and other network parameters showed no significant differences. DPCC decreased with increasing stage, indicating rising inter-lesion metabolic heterogeneity. Discussion: The DPCC of 18F-FDG PET/CT metabolic network connectivity is associated with clinical stage in DLBCL patients with multiple measurable lesions and may provide complementary network-level information. These exploratory findings require external validation in larger, multicenter cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.